Jowita Fraczkiewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jowita Fraczkiewicz has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Jan Styczyński
Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland
2 shared publications - Krzysztof Czyżewski
Department of Pediatric Oncology, Hematology and Transplantology, Institute of Pediatrics, Poznan University of Medical Sciences, 60-572 Poznan, Poland
2 shared publications Malgorzata Salamonowicz
Department of Pediatric Transplantation, Oncology and Hematology, Medical University, Wroclaw, Poland
2 shared publicationsAgnieszka Gietka
Department of Oncology, Children's Memorial Health Institute, Warsaw, Poland
1 shared publicationAgnieszka Zaucha-Prazmo
Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical University, Lublin, Poland
1 shared publication- Barbara Tejza1 shared publication
Latest Publications
- 1 September 2024
- Published by Evereth Publishing in Forum Zakażeń
- Vol. 15 (3) , 75-81
Postępowanie diagnostyczno-terapeutyczne w grzybiczym zapaleniu zatok obocznych nosa: stan wiedzy i zalecenia ekspertów Polskiego Towarzystwa Onkologii i Hematologii Dziecięcej
Inwazyjne grzybicze zapalenie zatok przynosowych (IFS) u dzieci jest chorobą infekcyjną występującą u pacjentów z obniżoną odpornością, charakteryzującą się dużym ryzykiem powikłań oraz wysoką śmiertelnością. Klasyfikacja grzybiczego zapalenia zatok obejmuje postaci inwazyjne i nieinwazyjne. Do postaci inwazyjnych zalicza się 3 podtypy: ostre inwazyjne grzybicze zapalenie zatok, przewlekłe inwazyjne grzybicze zapalenie zatok oraz przewlekłe ziarniniakowe inwazyjne grzybicze zapalenie zatok. Postaci nieinwazyjne grzybiczego zapalenia zatok obejmują alergiczne grzybicze zapalenie zatok oraz mycetomię (kula grzybicza, grzybniak). Poszczególne podtypy różnią się cechami klinicznymi i radiologicznymi, co wpływa na zróżnicowane strategie leczenia oraz rokowanie. Kluczowe znaczenie ma szybka diagnoza i wdrożenie odpowiedniego leczenia. Diagnostyka opiera się na tomografii komputerowej (TK) oraz rezonansie magnetycznym (MRI). Celem pracy jest przedstawienie zasad postępowania diagnostyczno-terapeutycznego w grzybiczym zapaleniu zatok obocznych nosa opracowanych przez grupę ekspertów Polskiego Towarzystwa Onkologii i Hematologii Dziecięcej.
- 1 September 2024
- Published by Evereth Publishing in Forum Zakażeń
- Vol. 15 (3) , 75-81
Postępowanie diagnostyczno-terapeutyczne w grzybiczym zapaleniu zatok obocznych nosa: stan wiedzy i zalecenia ekspertów Polskiego Towarzystwa Onkologii i Hematologii Dziecięcej
Inwazyjne grzybicze zapalenie zatok przynosowych (IFS) u dzieci jest chorobą infekcyjną występującą u pacjentów z obniżoną odpornością, charakteryzującą się dużym ryzykiem powikłań oraz wysoką śmiertelnością. Klasyfikacja grzybiczego zapalenia zatok obejmuje postaci inwazyjne i nieinwazyjne. Do postaci inwazyjnych zalicza się 3 podtypy: ostre inwazyjne grzybicze zapalenie zatok, przewlekłe inwazyjne grzybicze zapalenie zatok oraz przewlekłe ziarniniakowe inwazyjne grzybicze zapalenie zatok. Postaci nieinwazyjne grzybiczego zapalenia zatok obejmują alergiczne grzybicze zapalenie zatok oraz mycetomię (kula grzybicza, grzybniak). Poszczególne podtypy różnią się cechami klinicznymi i radiologicznymi, co wpływa na zróżnicowane strategie leczenia oraz rokowanie. Kluczowe znaczenie ma szybka diagnoza i wdrożenie odpowiedniego leczenia. Diagnostyka opiera się na tomografii komputerowej (TK) oraz rezonansie magnetycznym (MRI). Celem pracy jest przedstawienie zasad postępowania diagnostyczno-terapeutycznego w grzybiczym zapaleniu zatok obocznych nosa opracowanych przez grupę ekspertów Polskiego Towarzystwa Onkologii i Hematologii Dziecięcej.
- Open Access
- 1 December 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 3893-3902
Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein–Barr Virus Reactivation
Objective: The analysis of epidemiology, risk factors and outcome of viral infections in children and adolescents after hematopoietic cell transplantation (HCT). Methods: In this multicenter nationwide study a total of 971 HCT procedures (741 allo-HCT; 230 auto-HCT) over a period of 6 years were analyzed. Results: During this period 801 episodes of viral infections were diagnosed in 442 patients. The incidence of viral infections was 57.9% in allo-HCT and 4.8% in auto-HCT patients. The most frequent infections after allo-HCT were caused by cytomegalovirus (CMV), polyoma BK virus (BKV) and Epstein–Barr virus (EBV). The majority of infections occurred within the first 4 months after allo-HCT and over 80% required pharmacotherapy or symptomatic therapy. The median time of treatment of specific viral infection ranged from 7 (for EBV) to 24 (for CMV) days. The highest mortality was observed in case of CMV infection. The risk factors for viral infections were allo-HCT, acute leukemia, acute and chronic graft versus host disease (a/cGVHD), and matched unrelated donor (MUD)/mismatched unrelated donor (MMUD)-HCT. The risk factor for death from viral infection were CMV-IgG seropositivity in acute lymphoblastic leukemia recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring pre-emptive treatment with rituximab in allo-HCT children was 19.3%. In 30.8% cases of EBV infection, these episodes were preceded by other viral infection and treated with antivirals, which did not prevent development of EBV-DNA-emia with need of rituximab treatment in 81.5% cases. In 47.7% of these cases, GVHD was a factor enabling development of significant EBV-DNA-emia during antiviral therapy of other infection. Conclusion: We have shown that antiviral drugs do not prevent EBV reactivation in allo-HCT pediatric patients.
- 1 December 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 3893-3902
Open AccessEpidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein–Barr Virus Reactivation
Objective: The analysis of epidemiology, risk factors and outcome of viral infections in children and adolescents after hematopoietic cell transplantation (HCT). Methods: In this multicenter nationwide study a total of 971 HCT procedures (741 allo-HCT; 230 auto-HCT) over a period of 6 years were analyzed. Results: During this period 801 episodes of viral infections were diagnosed in 442 patients. The incidence of viral infections was 57.9% in allo-HCT and 4.8% in auto-HCT patients. The most frequent infections after allo-HCT were caused by cytomegalovirus (CMV), polyoma BK virus (BKV) and Epstein–Barr virus (EBV). The majority of infections occurred within the first 4 months after allo-HCT and over 80% required pharmacotherapy or symptomatic therapy. The median time of treatment of specific viral infection ranged from 7 (for EBV) to 24 (for CMV) days. The highest mortality was observed in case of CMV infection. The risk factors for viral infections were allo-HCT, acute leukemia, acute and chronic graft versus host disease (a/cGVHD), and matched unrelated donor (MUD)/mismatched unrelated donor (MMUD)-HCT. The risk factor for death from viral infection were CMV-IgG seropositivity in acute lymphoblastic leukemia recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring pre-emptive treatment with rituximab in allo-HCT children was 19.3%. In 30.8% cases of EBV infection, these episodes were preceded by other viral infection and treated with antivirals, which did not prevent development of EBV-DNA-emia with need of rituximab treatment in 81.5% cases. In 47.7% of these cases, GVHD was a factor enabling development of significant EBV-DNA-emia during antiviral therapy of other infection. Conclusion: We have shown that antiviral drugs do not prevent EBV reactivation in allo-HCT pediatric patients.
- Open Access
- 1 May 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 1471-1480
Infectious complications in children with malignant bone tumors: a multicenter nationwide study
Objectives: The analysis of epidemiology, risk factors and outcome of infections in children with malignant bone tumors (MBT) undergoing chemotherapy. Methods: In this retrospective nationwide multicenter cross-sectional study, a total number of 126 children with MBT including 70 with Ewing sarcoma (ES) and 56 with osteosarcoma (OSA) were screened for infections over a period of 72 consecutive months. Results: The risk of infection was 7.15-fold higher in patients with ES as compared to the OSA group, especially concerning bacterial infections (4.1-fold increase risk). Bacterial infections occurred in 74.3% patients with ES and in 41.1% with OSA. The median time from diagnosis to first infection was 4.9 months. 33.0% of bacterial episodes were diagnosed as bloodstream (BSI), 31.1% as gastrointestinal tract, 30.1% as urinary tract infection. Infection-related mortality (IRM) from bacterial infection was 6% and 15% in ES and OSA patients, respectively. Cumulative incidence was 7.1% for invasive fungal disease and 6.3% for viral infections. The only significant risk factor for IRM was time to infection ≥5 months since the beginning of chemotherapy. All patients who have died from infection had BSI and were in neutropenia. Conclusions: Infections in the children with MBT in our study occurred with high frequency, especially in patients with ES. The most frequent were bacterial infections, while fungal and viral infections were episodic. Among the bacterial infections, bloodstream, urinary tract and gastrointestinal tract infections occurred with similar frequency. All deceased patients died due to BSI. Bacterial infection occurring ≥5 months since the beginning of chemotherapy was a risk factor for death.
- 1 May 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 1471-1480
Open AccessInfectious complications in children with malignant bone tumors: a multicenter nationwide study
Objectives: The analysis of epidemiology, risk factors and outcome of infections in children with malignant bone tumors (MBT) undergoing chemotherapy. Methods: In this retrospective nationwide multicenter cross-sectional study, a total number of 126 children with MBT including 70 with Ewing sarcoma (ES) and 56 with osteosarcoma (OSA) were screened for infections over a period of 72 consecutive months. Results: The risk of infection was 7.15-fold higher in patients with ES as compared to the OSA group, especially concerning bacterial infections (4.1-fold increase risk). Bacterial infections occurred in 74.3% patients with ES and in 41.1% with OSA. The median time from diagnosis to first infection was 4.9 months. 33.0% of bacterial episodes were diagnosed as bloodstream (BSI), 31.1% as gastrointestinal tract, 30.1% as urinary tract infection. Infection-related mortality (IRM) from bacterial infection was 6% and 15% in ES and OSA patients, respectively. Cumulative incidence was 7.1% for invasive fungal disease and 6.3% for viral infections. The only significant risk factor for IRM was time to infection ≥5 months since the beginning of chemotherapy. All patients who have died from infection had BSI and were in neutropenia. Conclusions: Infections in the children with MBT in our study occurred with high frequency, especially in patients with ES. The most frequent were bacterial infections, while fungal and viral infections were episodic. Among the bacterial infections, bloodstream, urinary tract and gastrointestinal tract infections occurred with similar frequency. All deceased patients died due to BSI. Bacterial infection occurring ≥5 months since the beginning of chemotherapy was a risk factor for death.